Cardiotoxicity of Anticancer Therapies

Area of Science:

• Oncology and Cardiology
• Cardio-oncology

Background:

• Cardiovascular diseases and cancer are leading causes of death.
• Cancer survival rates have improved due to advancements in chemotherapy and early diagnosis.
• Improved cancer survival leads to increased risk of late-onset cardiovascular disease, potentially from shared risk factors or cardiotoxic cancer therapies.

Purpose of the Study:

• To review the cardiac effects of common chemotherapeutic agents.
• To highlight the importance of identifying and managing cardiotoxicity in cancer patients.

Main Methods:

• Review of existing literature on cardiotoxicity associated with various chemotherapeutic agents.
• Analysis of the mechanisms and clinical manifestations of adverse cardiac events in cancer patients undergoing chemotherapy.

Main Results:

• Chemotherapy agents can cause a wide range of adverse cardiac effects.
• Cardiotoxicity is a significant concern for long-term cancer survivors.
• Early identification and intervention are key to mitigating cardiac morbidity.

Conclusions:

• Cardiotoxicity is an important consideration in cancer treatment.
• Monitoring and proactive management of cardiac health are essential for patients receiving chemotherapy.
• Further research is needed to develop strategies for preventing and treating chemotherapy-induced cardiotoxicity.